Market closed

Atossa Therapeutics/$ATOS

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Atossa Therapeutics

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Ticker

$ATOS

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Seattle, United States

Employees

Website

www.atossatherapeutics.com

ATOS Metrics

BasicAdvanced

$110M

-

-$0.21

1.23 -

Price and volume

Market cap

$110M

Beta

1.23

52-week high

$2.31

52-week low

$0.77

Average daily volume

916K

Financial strength

Current ratio

13.304

Quick ratio

12.9

Management effectiveness

Return on assets (TTM)

-20.35%

Return on equity (TTM)

-31.30%

Valuation

Price to book

1.49

Price to tangible book (TTM)

1.49

Price to free cash flow (TTM)

-5.608

Growth

Earnings per share change (TTM)

-9.15%

3-year earnings per share growth (CAGR)

-11.60%

What the Analysts think about ATOS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Atossa Therapeutics stock.

ATOS Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

ATOS Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

ATOS News

AllArticlesVideos

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

GlobeNewsWire·1 month ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

GlobeNewsWire·1 month ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

GlobeNewsWire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ATOS

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Atossa Therapeutics stock?

Atossa Therapeutics (ATOS) has a market cap of $110M as of January 15, 2025.

What is the P/E ratio for Atossa Therapeutics stock?

The price to earnings (P/E) ratio for Atossa Therapeutics (ATOS) stock is 0 as of January 15, 2025.

Does Atossa Therapeutics stock pay dividends?

No, Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Atossa Therapeutics dividend payment date?

Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders.

What is the beta indicator for Atossa Therapeutics?

Atossa Therapeutics (ATOS) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.